United States: FDA Begins To Update How It Regulates Software Used As A Medical Device

Last Updated: February 27 2018
Article by Adrian Mollo and Edward Dougherty

The US Food and Drug Administration (FDA) is considering changes to the regulatory pathways for software used as a medical device (SaMD). Members of Dentons' Life Sciences team attended FDA's public meeting, "Fostering Digital Health Innovation: Developing the Software Precertification Program," held January 30 and 31 on the campus of the National Institutes of Health (NIH) in Bethesda, Maryland. Here are our key takeaways from that meeting.

What is software as a medical device?

Software as a medical device is defined by the International Medical Device Regulators Forum (IMDRF) as "software intended to be used for one or more medical purposes that performs these purposes without being part of a hardware medical device." FDA has also provided definitions and examples of software that it intends to regulate as a medical device (such as treatment-planning software that supplies information used in a linear accelerator) and contrasts that with other software products that will not be regulated as a medical device (such as encryption software that relies on data from a medical device, but does not have a medical purpose). A comprehensive list of definitions and examples can be found on the FDA's website.

Hardware vs. software: Does it call for a different regulatory approach?

Recognizing that the traditional process of reviewing medical devices no longer fits, FDA has worked to develop a more streamlined process for premarket review and clearance of software products regulated as medical devices. The new process is intended to be better calibrated to the development, maintenance and lifespan of software products and services.

For example, consider the role and function of the design history file (DHF) in the traditional medical device development process. The DHF should contain (among the other requirements of 21 CFR Part 820.30), records related to development activity, design outputs required to build the device, design verification and validation protocols, and everything required to transfer the device to manufacturing (whether internal or a contract manufacturer). Although those requirements reflect the more traditional notion of a medical device, they no longer match up to the typical software development and verification process. In addition, compared to hardware, which may be designed to continue to be used without modification for extended periods (especially in the case of implantable medical devices), software is regularly patched, updated and even replaced, often several times a year.

When FDA launched a new Precertification Pilot Program for companies developing SaMD in August 2017, the agency acknowledged the situation and noted that its

traditional approach to moderate and higher risk hardware-based medical devices is not well suited for the faster iterative design, development and type of validation used for software products. An agile paradigm is necessary to accommodate the faster rate of development and innovation of software devices as compared to other types of devices. Traditional implementation of the premarket requirements may impede or delay patient access to critical evolutions of software technology, particularly those presenting a lower risk to patients.


FDA's Software Precertification Program

When FDA announced the Software Precertification Pilot Program last summer, it indicated that a new regulatory review process for SaMD may include (a) precertification of digital health developers, for those developers that reliably manufacture high-quality, safe and effective digital health devices while providing appropriate patient safeguards, (b) an avenue by which pre-certified developers may market their lower-risk devices without additional FDA review or with a more streamlined premarket review and (c) collection by those developers of real-world postmarket data, to affirm the regulatory status of the product, as well as to support new and evolving product functions. The first component, precertification, has been the agency's focus for the past several months.

As the first step in the Precertification Pilot Program, FDA worked with nine pilots partners—Apple, Fitbit, Johnson & Johnson, Pear Therapeutics, Phosphorous, Roche, Samsung, Tidepool and Verily—to solicit their perspectives on what makes their companies' operations excellent, what practices and processes they put in place to create and maintain excellence, and how they know that those practices and processes are working. The pilot participants and FDA also considered how their approaches to operational excellence align with the excellence principles and common validating processes proposed by FDA. The agency then published a report on its visits to the nine pilot participants.

With regard to precertification, FDA appears ready to establish standards for "organizational excellence," under which an organization (rather than a particular device) might be pre-certified. The initial approach focuses on patient safety, product quality, clinical responsibility, cybersecurity responsibility and proactive culture. If an organization is pre-certified under these excellence standards, the organization may be entitled to launch new SaMDs with reduced premarket review requirements. Those organizations may also have lower reporting and qualification requirements before, for example, rolling out update and new versions. Eventually, FDA may authorize other competent authorities to precertify software designs and manufacturers, similar to the way the European Union relies on notified bodies to help manufacturers qualify medical devices for a European Conformity (CE) mark.

The workshops

As part of the public meeting, FDA invited stakeholders to attend as the "tenth pilot partner." The agency convened workshops at which pre-certification pilot companies endorsed its step toward "right-sizing" the regulation of digital health. One participant from FDA noted that, although the agency will always maintain rigorous oversight of device safety and effectiveness, "nothing is sacred"—suggesting a willingness to reconsider and reconceive how those ends are accomplished.

Next steps in developing a software pre-cert program

The workshops not only provided an update from FDA, they also invited stakeholder input. Some of the open issues identified during the workshops included:

  • Whether the pre-cert program would take the place of a traditional 510(k) or pre-market approval (PMA) review process for software products intended for use as medical devices
  • Whether the pre-cert program would change the standards or length of premarket review (presumably the focus of the next phase of updating the regulation of SaMD)
  • Discussion of the standards that would be used to measure organizational excellence, such as international standards or an FDA-developed model
  • How payers might evaluate SaMD products for coverage and reimbursement, if SaMD products were cleared for market without clinical and other data that would currently be required for premarket review
  • How the pre-cert program might change the current approach to premarket review for software products and related services (for example, the DHF)
  • How FDA will likely manage the process of certifying organizational excellence, including whether it may establish standards for outsourcing precertification
  • How the emerging new regulatory pathway might apply to "software in a medical device" (SiMD)

To help build this pathway, and to answer these and many other open questions, the FDA has issued a call to stakeholders: "We cannot build this program to create the right incentives, solve the right problems, and produce the right outcomes for public health without input and collaboration from all stakeholders."

To that end, and until March 1, 2018, stakeholders are invited to offer comment and recommendations at FDA's website. Although the process of updating the regulation of software products and services will take the next few years, this is the beginning of a process that is poised to radically change the clearance process for software as a medical device and digital health. Any businesses interested in the future of digital health should consider stepping forward and participating in the creation of this regulatory pathway.

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
26 Sep 2018, Conference, New York, United States

Dentons is delighted to support a global IT services and consulting firm Miratech as an event host partner at their annual conference called M-Force18 New York on September 27th. The event will be held at Dentons New York office in the heart of Midtown Manhattan, opposite Rockefeller Center.

2 Oct 2018, Seminar, Dallas, United States

We are pleased to offer a program of five sessions designed specifically for in-house counsel. Topics will include:

  • In-house corporate ethical issues
  • What recent Supreme Court decisions mean for business
  • Keeping lawyers out of your benefit plans
  • Litigation tactics for in-house counsel
  • Employment issues in the age of #MeToo
Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions